| Term 
 | Definition 
 
        | Alkylating Agent (nitrogen mustard)   Low emetogenic potential   Use:  CML   SE:  hepatic veno-occlusive disease, pulmonary fibrosis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | alkylating agents (nitrogen mustards)   SE:  pulmonary toxicity, thrombocytopenia   oral |  | 
        |  | 
        
        | Term 
 
        | cyclophosphamide (Cytoxan) |  | Definition 
 
        | Alkylating Agent - nitrogen mustard   Use:  breast, ovarian, prostate, and lunch   Non-oncology uses:  RA, glomerulonephritis   SE:  metabolite is acrolein which causes hemorrhagic cystitis, SIADH   Prevent SE with lots of hydration and optional infusion of Mesna |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | alkylating agent - nitrogen mustard   Use:  lung, testicular, lymphomas and sarcomas   ALWAYS GIVE WITH MESNA (not optional like with cyclophosphamide) |  | 
        |  | 
        
        | Term 
 
        | mechlorethamine (Mustargen) |  | Definition 
 
        | alkylating agent - nitrogen mustard   one of the original   Use:  multiple including polycythemia vera, CLL, CML, hodgkins disease   Part of MOPP regimen |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | alkylating agent - nitrogen mustard   Use:  lymphomas, breast, ovarian   SE:  BMS especially thrombocytopenia   DO NOT CRUSH TABLETS |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | alkylating agent - nitrogen mustard   Use:  bladder   SE:  BMS |  | 
        |  | 
        
        | Term 
 
        | carmustine (BiCNU)   lomustine (CeeNU)   streptozocin (Zanosar) |  | Definition 
 
        | Nitrosoureas   All used in brain malignancies (good brain penetration)   High emetogenic potential   SE:  leukopenia about 3-5 weeks after therapy   prolonged carmustine associated with pulmonary toxicity |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Platinum analogues   cisplatin analogue with less nepthrotoxicity but more BMS   dose based on AUC (most CA drugs weight based mg/m2)     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Platinum analogues   Use:  testicular, ovarian, lung, head and neck   SE:  high emotogenic potential**, nephrotoxicity, ototoxicity, peripheral neuropathy, hypoMg     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Platinum analogues   Use:  melanomas, hodgkins disease, sarcomas   SE:  severe N/V |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Platinum analogues   Use:  hodgkins and other lymphomas   Drug interactions with MAOIs and TCAs and tyromine containing foods.  disulfiram reaction   SE:  CNS (depression) |  | 
        |  | 
        
        | Term 
 
        | daunorubicin (Cerubidine) |  | Definition 
 
        | Anthracyclines -cardiotoxicity!!   Patients get pre-treatment either ECHO or MUGA   SE:  cardiotoxicity, alopecia, stomatitis   Dose limit of 550mg/m2   liposomal formulation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Anthracyclines   SE:  urine discoloration (red)   Dose limit of 550mg/m2   liposomal formulation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Anthracyclines     lifetime dose is 137.5mg/m2 |  | 
        |  | 
        
        | Term 
 
        | mitoxantrone (Novantrone) |  | Definition 
 
        | Anthracyclines   lifetime dose is 150mg/m2   Urine blue-green color   Used in MS patients     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Iron chelator used to prevent oxygen free radicals and cardiotoxicity   Dose:  500mg/m2 of zinecards for every 50mg/m2 of doxorubicin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Other antibiotics   Uses:  hodgkins lympohma, testicular   SE:  pulmonary toxicity especially w/ doses >200U/m2 (cumulative dose), mucositis, BMS |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Other antibiotics   SE:  mucositis, BMS |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Other antibiotics   SE:  stomatitis |  | 
        |  | 
        
        | Term 
 
        | methotrexate (Amethopterin) |  | Definition 
 
        | MTX   Antimetabolites - folic acid antagonist   Uses:  RA, psoriasis, ectopic pregnancy, variety   SE:  BMS   leucovorin rescue:  10-100mg/m2 q6h until MTX levels fall, used with high dose MTX (1g/m2)       |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | used to lower methotrexate levels to prevent BMS   especially used when giving high doses of methotrexate (1g/m2) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | ARA-C   Antimetabolites   Use:  Induction phase of AML   SE:  myelosuppression common with HIDAC, conjunctivitis (give corticosteroid eye drops) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Antimetabolite - purine antagonist   Use:  CLL   SE:  BMS, neurotoxicity, pulmonary toxicity   BMS can be severe so sometimes will prophylax with bactrim |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Anti-metabolite - purine antagonist   Use:  ALL and chronic leukemia   allopurinol inhibits its metabolism so must dose reduce (75%)   SE:  cholestatic liver dysfunction |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Antimetabolite - purine antagonist   Use:  Hairy cell leukemia   SE:  neutropenia and drug fever |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Antimetabolite - purine antagonist   SE:  nephrotoxic (hydrate well), drug fever   Use:  Hairy cell leukemia |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | antimetabolite - pyrimidine antagonist   Use:  pancreatic   SE:  neutropenia, increased liver enzymes |  | 
        |  | 
        
        | Term 
 
        | fluorouracil (Adrucil) 5-FU |  | Definition 
 
        | antimetabolite - pyrimidine antagonist   Use:  breast, colon, head/neck   May add leucovorin for increased colon Ca response   SE:  BMS and mucositis, low N |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | antimetabolite - pyrimidine antagonist   Use:  colorectal, metastatic breast   oral 5-FU basically   SE:  lots of pts stops due to GI   Treat in 2 week oral cycles |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | antimetabolite - pyrimidine antagonist   can cause some drying or darkening of nails and hair (sunlight makes worse) |  | 
        |  | 
        
        | Term 
 
        | vincristine (Oncovin)   vinorelbine (Navelbine)   vinblastine (Velban) |  | Definition 
 
        | Vinca Alkaloids   SE:  vincristine and vinblastine are vesicants so they can cause major damage to surrounding tissues on administration   neurotixic medications   dose max of vincristine is 2mg**   do not give vincristine intrathecally |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Epipodophyllotoxin   Oral and IV   Refridgerate   SE:  well tolerated; some alopecia and mucositis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Epipodophyllotoxin   SE:  hypotension and hypersensitivity     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Taxanes   Used:  lung, ovarian, breast   SE:  neutopenia (greater with 24 hr infusion), bradycardia, neurotoxicity with parasthesia   Premed with H-2 antagonists, steroids, H-1 antagonists to help with hypersensitivity reaction |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Taxanes   SE:  neutropenia, fluid retention w/ high cumulative doses (>500mg/m2)   pretreat with dexamethasone for 3-5 days prior to administration |  | 
        |  | 
        
        | Term 
 
        | topotecan (Hycamtin)   irinotecan (Camptosar)     |  | Definition 
 
        | camptothecins   SE:  severe diarrhea (give some loperamide incase) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Biologics   works on HER2 protein, if HER2 + = good candidate   Use:  breast   SE:  cardiotoxicity (baseline ECHO or MUGA), infusion reactions (premed with APAP) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Monoclonal antibody that binds to CD20 antigen expressed in many B-cell NHL lymphomas   if CD20 + = good candidate for rituximab   Use:  B-cell lymphoma as well as follicular lymphoma   SE:  infusion related reactions that have resulted in death!  Especially the initial infusion, hypoxia, pulmonary infiltrates, MI, Vfib, start low go slow |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Requires a test dose for administration   Used:  ALL   SE:  hyperglycemia, CNS disturbances, pancreatitis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Used:  leukemia, sickle cell, Essentrial thrombocytosis (ET) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | antiestrogen compound  (oral)   Used:  breast   SE:  flushing, weight gain (premenopausal patients) |  | 
        |  | 
        
        | Term 
 
        | anastrazole (Arimidex)   letrozole (Femara) |  | Definition 
 
        | Aromatase inhibitors   Used:  breast   Used in postmenopausla patients   SE:  HTN, flushing, mood disturbances |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Used to prevent cisplatin induced nephron and neurotoxicity   Dose:  910mg/m2 over 15 min   SE:  transient hypotension |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 5-HT3   40 hr 1/2 life, give one dose |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | antiemetic   used with refractory N/V or in cisplatin containing regimens   Dose:  125mg 1 hr before chemo (day 1) and then 80mg once daily on Day 2 and 3 |  | 
        |  | 
        
        | Term 
 
        | G-CSF (Neupogen or Neulasta)   GM-CSF (Sargramostim or Leukine) |  | Definition 
 
        | Colony stimulating factors   Used:  Treats neutropenia by stimulating bone marrow   Neulasta is pegfilgrastim (SQ injection one time 24 hours after cycle)   SE:  bone pain   refridgerate |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Oral Epidermal Growth Factor Class    Used:  non-small cell lung CA   Dose:  150mg 1hr before or 2hr after food   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | monoclonal antibody   SE:  infusion related reactions for all monoclonal antibodies, HTN, Headache |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | SE:  infusion reactions, fever, sepsis, PE, kidney failure |  | 
        |  | 
        
        | Term 
 
        | Epoetin alfa (Epogen/Procrit)   darbepoeitin (Aranesp) |  | Definition 
 
        | Used for chemotherapy induced anemia or CKD induced anemia   SE:  hypersensitivity to the albumin, increase risk of cardiovascular events (MI, stroke), may increase risk of certain CA (breast, cervical, head and neck)   darbopoeitin - longer 1/2 life |  | 
        |  |